About 9,300 results
Open links in new tab
  1. The New England Journal of Medicine | Research & Review Articles …

    3 days ago · The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide …

  2. Antibiotic Treatment for 7 versus 14 Days in Patients with …

    Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In …

  3. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …

    Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …

  4. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

    Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or …

  5. Lepodisiran - The New England Journal of Medicine

    Mar 30, 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small …

  6. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

    Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl …

  7. Zongertinib in Previously Treated - The New England Journal of …

    Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is …

  8. Encorafenib, Cetuximab, and mFOLFOX6 in - The New England …

    May 30, 2025 · First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF …

  9. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

    Feb 7, 2025 · In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules …

  10. Xenotransplantation of a Porcine Kidney for End-Stage Kidney …

    Feb 7, 2025 · Kidney transplantation has become the ideal standard of care for end-stage kidney disease, but organ shortage remains critical. 1 One promising approach to address this critical …